Under construction – not a live service
Sign in
Taking people in United KingdomPhase 2

Using a PSMA scan to plan melanoma surgery

Tests a PSMA PET scan to find melanoma spread before surgery in adults.

Plain-language title generated from the registry record
Registry title: Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Key facts

Where
London, United KingdomSee the site
Phase
Phase 2

Where in United Kingdom

  • The Royal Marsden NHS Foundation TrustLondon, United KingdomTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Royal Marsden NHS Foundation Trust
Trial code
NCT06560905
Record updated
1 July 2025
Original description
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.Read full original descriptionShow less

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Inclusion: Males ≥18 years of age; Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site.

Exclusion: Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists; Patients who have or have previously been diagnosed with prostate cancer; Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning; Patients unable to give voluntary written informed consent to participate in this study; Patients not willing to complete all the study assessments; Patients who are females; Patients not fluent in English.

ClinicalTrials.gov NCT06560905